Skip to main content
BioSyent Inc. logo

BioSyent Inc. — Investor Relations & Filings

Ticker · RX ISIN · CA0906901081 TSXV Manufacturing
Open in API
Filings indexed 182 across all filing types
Latest filing 2025-03-13 Audit Report / Informat…
Country CA Canada
Listing TSXV RX

About BioSyent Inc.

https://www.biosyent.com/

BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company focused on enhancing patient lives by addressing unmet medical needs. The company's primary business model involves sourcing, in-licensing, and acquiring innovative pharmaceutical and healthcare products globally for development and commercialization. BioSyent markets a diverse portfolio of products, including prescription, over-the-counter, and behind-the-counter options, primarily serving markets in Canada and select international regions.

Recent filings

Filing Released Lang Actions
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 1% confidence The document is the audited consolidated financial statements of BioSyent Inc. for the years ended December 31, 2024 and 2023, including Management’s Responsibility section and the Independent Auditor’s Report by MNP LLP. It is a standalone audit report rather than an Annual Report announcement or a brief notice, and there is no indication that it is merely an announcement of an attached report. Therefore, it fits the definition of an Audit Report / Information (Code: AR). FY 2024
2025-03-13 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release titled “BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024,” presenting key financial highlights, summary tables of consolidated income and balance sheet data, commentary from the CEO, and dividend/share repurchase information. It is an initial public announcement of quarterly and annual results rather than a full annual or interim report filing, fitting the definition of an Earnings Release. Q4 2024
2025-03-13 English
News release - English.pdf
Report Publication Announcement Classification · 1% confidence The document is a press release announcing the date and schedule for BioSyent’s upcoming fourth quarter and full year 2024 earnings release, rather than providing the actual financial results themselves. It states when the report will be published and that a presentation will be available on the company’s website on that date. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing and publication of company reports.
2025-03-06 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a regulatory notice filed with the Canadian Securities Regulatory Authorities providing details of the upcoming annual and special meeting (record date, meeting date, location, notice and access parameters, CUSIP/ISIN). It is not the full proxy circular or information statement sent to shareholders, nor is it a post‐meeting voting results announcement. It simply notifies regulators of meeting details and thus does not align with any of the more specific categories. It is best classified under the general Regulatory Filings (RNS) fallback.
2025-03-03 English
News release - English.pdf
Notice of Dividend Amount Classification · 1% confidence The document is a press release titled “BioSyent Declares First Quarter 2025 Dividend” and provides details on the dividend amount ($0.05 per share), payment date (March 14, 2025), record date (February 28, 2025), and qualifies as an eligible dividend. This matches the definition of a Notice of Dividend Amount (Code: DIV).
2025-01-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-11-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.